AUSTIN, Texas, Jan. 25, 2022 /PRNewswire/ -- Aeglea
BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology
company developing a new generation of human enzyme therapeutics to
benefit people with rare metabolic diseases, today announced that
it will host a Key Opinion Leader (KOL) and Patient Caregiver
Webinar on Arginase 1 Deficiency on Thursday, February 3, 2022, at 2:30pm EST.
The webinar will include presentations from:
- Barbara Burton, M.D., Professor
of Pediatrics, Northwestern University
Feinberg School of Medicine, and Attending Physician in the
Division of Genetics, Birth Defects and Metabolism at the Ann &
Robert H. Lurie Children's Hospital of Chicago, will provide
an overview of Arginase 1 Deficiency and describe the role of
arginine in the pathogenesis of the disease.
- George Diaz, M.D., Ph.D.,
Professor of Genetics and Genomic Sciences, Icahn School of
Medicine, and Director of the Program for Inherited Metabolic
Diseases at Mount Sinai
(New York, NY), will discuss
the enzyme therapy approach to treating patients with Arginase 1
Deficiency and clinical data.
- Tanja Brandt, parent/caregiver
of a 10-year-old child with Arginase 1 Deficiency, Advisor and
Steering Committee Member of the Arginase 1 Deficiency Foundation
(ARG1D.org), will discuss the disease burden and will provide
the patient and caregiver perspective related to the challenges of
living with a devastating and progressive disease.
A live question and answer session will follow the formal
presentations. To register for the webinar, please
click here. To access the live and/or archived webcast,
visit the Events & Presentations section of the
Company's website. Replays of Company
webcasts are archived on the website for 30 days
following presentations.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company
redefining the potential of human enzyme therapeutics to benefit
people with rare metabolic diseases with limited treatment options.
In December 2021, Aeglea announced
positive topline data from its PEACE Phase 3 clinical trial for its
lead product candidate, pegzilarginase, in patients with Arginase 1
Deficiency. Pegzilarginase has received both Rare Pediatric Disease
and Breakthrough Therapy designations. Aeglea also has an ongoing
Phase 1/2 clinical trial of AGLE-177 for the treatment of
Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease
Designation. Aeglea has an active discovery platform focused on
engineering small changes in human enzymes to have a big impact on
the lives of patients and their families. For more information,
please visit http://aeglea.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-upcoming-kol-and-patient-caregiver-webinar-on-arginase-1-deficiency-301466577.html
SOURCE Aeglea BioTherapeutics, Inc.
